CMS Considering Obesity Drug Coverage Under Medicare
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency is "open" to considering coverage of obesity drugs in light of a recent change to its obesity policy, but seeks comment on how it can legally do so, given the prohibition of weight loss drug coverage under the Medicare Modernization Act.
You may also be interested in...
Acomplia Pricing Likely To Follow Statin Model, Sanofi Says
Sanofi is considering a range of pricing options for the weight-loss/smoking cessation agent, company says; price will ultimately depend on labeling. Statin model would be appropriate if Sanofi can position the drug as long-term therapy to reduce adverse health outcomes.
Acomplia Pricing Likely To Follow Statin Model, Sanofi Says
Sanofi is considering a range of pricing options for the weight-loss/smoking cessation agent, company says; price will ultimately depend on labeling. Statin model would be appropriate if Sanofi can position the drug as long-term therapy to reduce adverse health outcomes.
USP Medicare Formulary Classes Should Use Mechanism Of Action, PhRMA Says
Subclasses should be based on other clinically relevant pharmacological characteristics, PhRMA tells USP pharmaceutical manufacturers forum. There should be enough classes to include the top 200 drugs for each of three Medicare subpopulations, PhRMA says.